Lynparza Poised For Growth With Broad Ovarian Cancer Approval

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.

OvarianCancer_1200x675

AstraZeneca PLC's poly ADP-ribose polymerase (PARP) inhibitor Lynparza has succeeded in getting a broad, competitive US label for the second-line maintenance treatment of ovarian cancer, regardless of mutation status, and is now poised to grow rapidly from a relatively small base.

Lynparza is partnered with Merck & Co. Inc., following a development deal announced in July, which also includes AstraZeneca's...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip